Given the high frequency of KIT mutations and consequent elevated expression of this gene in AML with t(8;21), the addition to chemotherapy of the multikinase inhibitor Dasatinib has been evaluated in adult patients, and the results showed a favorable outcome (34). This evidence concerns the gene KIT and acute myeloid leukemia.